Alnylam Pharmaceuticals
ALNY
#444
Rank
S$68.21 B
Marketcap
S$516.33
Share price
1.06%
Change (1 day)
57.25%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2025 (TTM): S$0.11

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is S$0.12. In 2023 the company made an earnings per share (EPS) of S-$4.55 an increase over its 2022 EPS that were of S-$11.98.

EPS history for Alnylam Pharmaceuticals from 2012 to 2025

Annual EPS

Year EPS Change
2025 (TTM)S$0.11
2023S-$4.55-62%
2022S-$11.9829.03%
2021S-$9.29-3.36%
2020S-$9.61-8.48%
2019S-$10.507.67%
2018S-$9.7539.74%
2017S-$6.9812.94%
2016S-$6.1838.84%
2015S-$4.45-32.88%
2014S-$6.63259.44%
2013S-$1.84-31.25%
2012S-$2.68

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Arrowhead Pharmaceuticals
ARWR
S-$1.61-1,488.89%๐Ÿ‡บ๐Ÿ‡ธ USA
Regeneron Pharmaceuticals
REGN
S$56.04 48,166.67%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
S-$3.53-3,144.44%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
S-$0.31-366.67%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
S-$0.94-911.11%๐Ÿ‡บ๐Ÿ‡ธ USA
Novartis
NVS
S$9.49 8,077.78%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
S$4.78 4,017.43%๐Ÿ‡ซ๐Ÿ‡ท France
Teva Pharmaceutical Industries
TEVA
S$0.81 600.00%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel